Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer

Tenho Hietanen, Tapani Hakala, Dace Baltina, Risto Johansson, Soile Numminen, Leena Helle, Ritva Valavaara, Eric Thölix

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

In an open phase II study conducted in Finland and Latvia, 73 postmenopausal women were treated with 240 mg of toremifene (Fareston) as first-line therapy for advanced breast cancer. Among the 56 patients evaluable for responses, 39% achieved objective responses [complete response (CR) plus partial response (PR)], 29% showed no change (NC), and 12% had progressive disease (PD). When all treated patients were included, the objective response rate was 47%. Several very long durations of responses up to 86 months and survival durations up to 95 months were observed. In assessable patients, the best objective response rates were seen in those with soft-tissue (74%) and visceral (60%) disease. In 54% of patients with very large inoperable primary cancers, a PR was achieved. Half of patients reported side effects, about 60% of which were mild; 30%, moderate; and 5%, severe. Based on response rate and safety, high-dose toremifene is useful as first-line therapy for advanced breast cancer.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalOncology
Volume11
Issue number5 SUPPL. 4
Publication statusPublished - 1997
Externally publishedYes

Field of Science

  • 3.2 Clinical medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer'. Together they form a unique fingerprint.

Cite this